Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 7803361 Therapeutic use of interleukin-2 mutants

Patent 7803361 was granted and assigned to University of Southern California on September, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
University of Southern California
University of Southern California
0
Date Filed
April 7, 2009
0
Date of Patent
September 28, 2010
0
Patent Application Number
12419960
0
Patent Citations Received
‌
US Patent 11981715 Tissue targeted immunotolerance with a CD39 effector
0
‌
US Patent 11779632 IL-2 muteins and uses thereof
‌
US Patent 11945852 IL-2 muteins and uses thereof
0
‌
US Patent 11965008 IL-2 muteins and uses thereof
0
‌
US Patent 11976103 Interleukin-2 muteins for the expansion of T-regulatory cells
0
Patent Inventor Names
Alan L. Epstein
0
Peisheng Hu
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
7803361
0
Patent Primary Examiner
‌
Prema Mertz
0

Find more entities like US Patent 7803361 Therapeutic use of interleukin-2 mutants

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.